Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673253 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL225434 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL1109091 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL6231982 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL17283030 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL225433 | 1.00 | GAA (0.54) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL403933 | 0.94 | RAB9A (0.56) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL12837602 | 0.94 | RAB9A (0.56) | GAAKMT2ASLC1A2TAS1R3TAS1R1 | |
| SCHEMBL1109093 | 0.91 | NPC1 (0.54) | GAATAS1R3TAS1R1LNPEPCA2 | |
| SCHEMBL12055633 | 0.91 | NPC1 (0.54) | GAATAS1R3TAS1R1LNPEPCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170313992-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-11-02 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9719071-B2 | Ketoreductase polypeptides for the production of azetidinone | CODEXIS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170121689-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-9580694-B2 | Ketoreductase polypeptides for the production of azetidinone | CODEXIS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2003024943-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ARYX THERAPEUTICS (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6498256-B2 | CATALYSTS FOR ASYMMETRIC ADDITION REACTIONS, FOR EXAMPLE OF HYDROGEN, TO PROCHIRAL UNSATURATED ORGANIC COMPOUNDS. | SOLVIAS AG (CH) | 2002-12-24 | — | — | US | disclosed |
| US-20020128486-A1 | Phosphinite-oxazolines and metal complexes | PFALTZ ANDREAS (CH) | 2002-09-12 | — | — | US | disclosed |
| US-20020062027-A1 | Phosphinite-oxazolines and metal complexes | SOLVIAS AG (CH) | 2002-05-23 | — | — | US | disclosed |
| EP-1191030-A2 | Phosphinite-oxazolines and metal complexes | Solvias AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6306203-B1 | FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING | XEROX CORPORATION | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | GAA 361/4885KMT2A 1192/4885SLC1A2 178/4885 |
| US-20020062027-A1 | Phosphinite-oxazolines and metal complexes | OXER1, OXGR1, H1-4 | GAA 4861/4885KMT2A 1894/4885SLC1A2 2286/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | GAA 29/4885KMT2A 1895/4885SLC1A2 2160/4885 |
| US-20020128486-A1 | Phosphinite-oxazolines and metal complexes | OXER1, OXGR1, H1-4 | GAA 4861/4885KMT2A 1894/4885SLC1A2 2286/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | GAA 1139/4885KMT2A 2611/4885SLC1A2 4157/4885 |
| US-20030027798-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | GAA 29/4885KMT2A 1895/4885SLC1A2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.